Associated Papers
Genome-wide metabolite quantitative trait loci analysis (mQTL) in red blood cells from volunteer blood donors.
Moore A et al.
The Journal of Biological Chemistry, 2022
Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy.
Bagdasaryan AA et al.
Cancers, 2022
Integrating transcriptomics, metabolomics, and GWAS helps reveal molecular mechanisms for metabolite levels and disease risk.
Yin X et al.
American Journal of Human Genetics, 2022
Computational and Experimental Analysis of Genetic Variants.
Prokop JW et al.
Comprehensive Physiology, 2022
Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.
Nthontho KC et al.
Pharmacogenomics and Personalized Medicine, 2022
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE et al.
Leukemia & Lymphoma, 2021
Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting.
Pongor LS et al.
Scientific Reports, 2020
Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
Takeuchi A et al.
Anticancer Research, 2020
The genetic landscape of the human solute carrier (SLC) transporter superfamily.
Schaller L et al.
Human Genetics, 2019
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review.
Kulma I et al.
Cancer Chemotherapy and Pharmacology, 2019
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.
Tecza K et al.
Oncotarget, 2016
Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients.
Agarwal G et al.
World Journal of Surgery, 2016
Pharmacogenetics driving personalized medicine: analysis of genetic polymorphisms related to breast cancer medications in Italian isolated populations.
Cocca M et al.
Journal of Translational Medicine, 2016
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
Simeon V et al.
International Journal of Molecular Sciences, 2015
Whole genome sequencing of an ethnic Pathan (Pakhtun) from the north-west of Pakistan.
Ilyas M et al.
Bmc Genomics, 2015
Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients.
Voon PJ et al.
British Journal of Clinical Pharmacology, 2013
Pharmacogenetics of genes across the doxorubicin pathway.
Jamieson D et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J et al.
British Journal of Cancer, 2010
Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients.
Lal S et al.
Pharmacogenomics, 2007